LOTUSATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOTUSATE (LOTUSATE).
LOTUSATE is a selective serotonin reuptake inhibitor (SSRI) that inhibits the reuptake of serotonin at the presynaptic neuronal membrane, enhancing serotonin activity in the central nervous system and thereby exerting antidepressant and anxiolytic effects.
| Metabolism | Primarily metabolized by the liver via cytochrome P450 enzymes, specifically CYP2D6 and CYP3A4, with minor contribution from CYP2C19. The major metabolic pathway is demethylation followed by glucuronide conjugation. |
| Excretion | Primarily renal excretion of unchanged drug (65-75%) with 15-20% as glucuronide conjugate; 10-15% eliminated via feces. |
| Half-life | Terminal elimination half-life is 3.5-4.5 hours in healthy adults; prolonged to 8-10 hours in moderate hepatic impairment, requiring dose adjustment. |
| Protein binding | 92-96% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.8-1.2 L/kg, indicating extensive tissue distribution (exceeds total body water). |
| Bioavailability | Oral: 85-95% (high first-pass metabolism minimal); Rectal: 70-80%. |
| Onset of Action | Oral: 30-45 minutes; Intravenous: 2-5 minutes; Intramuscular: 10-15 minutes. |
| Duration of Action | Oral: 6-8 hours (analgesic effect); IV: 4-6 hours; hepatic impairment may prolong duration. |
100 mg orally twice daily, with or without food.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥60 mL/min/1.73 m²: No adjustment. eGFR 30-59: Reduce to 50 mg twice daily. eGFR 15-29: 50 mg once daily. eGFR <15 or on dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce to 50 mg twice daily. Child-Pugh C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required based on age alone; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOTUSATE (LOTUSATE).
| Breastfeeding | Excretion into human milk unknown; due to potential for serious adverse effects in nursing infants (e.g., renal toxicity, immune suppression), recommend discontinuing breast-feeding or the drug. M/P ratio not established. |
| Teratogenic Risk | LOTUSATE is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cardiovascular anomalies) based on animal studies and postmarketing data. Second/third trimester: associated with fetal growth restriction, oligohydramnios, and fetal death. Use only if no alternative and patient is fully informed; consider emergency contraception if exposure occurs. |
■ FDA Black Box Warning
WARNING: SUICIDAL THOUGHTS AND BEHAVIORS - Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. Monitor closely for worsening or emergence of suicidal thoughts and behaviors.
| Serious Effects |
Concomitant use with MAOIs (monoamine oxidase inhibitors) or within 14 days of MAOI therapy; concomitant use with linezolid or intravenous methylene blue; hypersensitivity to LOTUSATE or any excipients; severe hepatic impairment (Child-Pugh Class C).
| Precautions | Serotonin syndrome, particularly when co-administered with other serotonergic drugs; increased risk of bleeding, especially with NSAIDs or anticoagulants; activation of mania/hypomania; hyponatremia; seizure risk; angle-closure glaucoma; QT interval prolongation; discontinuation syndrome upon abrupt withdrawal. |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function, liver enzymes, and blood counts monthly during treatment. Perform fetal ultrasound for growth and amniotic fluid volume every 4 weeks if exposed in second/third trimester. Consider fetal echocardiography if exposure in first trimester. |
| Fertility Effects | Reversible impairment of spermatogenesis and oogenesis observed in animal studies. Reduced fertility reported in humans; advise pre-treatment fertility counseling. Effects likely resolve after drug discontinuation. |